Annual SG&A
$14.15 M
-$1.19 M-7.78%
31 December 2022
Summary:
Zynerba Pharmaceuticals annual selling, general & administrative expenses is currently $14.15 million, with the most recent change of -$1.19 million (-7.78%) on 31 December 2022. During the last 3 years, it has fallen by -$2.26 million (-13.75%).ZYNE Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$3.97 M
+$576.40 K+16.99%
30 June 2023
Summary:
Zynerba Pharmaceuticals quarterly selling, general & administrative expenses is currently $3.97 million, with the most recent change of +$576.40 thousand (+16.99%) on 30 June 2023.ZYNE Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.12 B
-$37.58 M-3.47%
30 June 2023
Summary:
Zynerba Pharmaceuticals TTM selling, general & administrative expenses is currently -$1.12 billion, with the most recent change of -$37.58 million (-3.47%) on 30 June 2023.ZYNE TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZYNE Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -13.8% | +2.6% | -7061.0% |
| 5 y5 years | +6.9% | +12.4% | -8571.3% |
ZYNE Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -13.7% | -13.2% | -6932.6% |
Zynerba Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $3.97 M(+17.0%) | $14.03 M(+1.8%) |
| Mar 2023 | - | $3.39 M(+5.4%) | $13.79 M(-2.6%) |
| Dec 2022 | $14.15 M(-7.8%) | $3.22 M(-6.8%) | $14.15 M(-4.0%) |
| Sept 2022 | - | $3.45 M(-7.2%) | $14.75 M(-2.7%) |
| June 2022 | - | $3.72 M(-0.9%) | $15.16 M(-4.2%) |
| Mar 2022 | - | $3.76 M(-1.5%) | $15.83 M(+3.1%) |
| Dec 2021 | $15.35 M(-6.5%) | $3.81 M(-1.4%) | $15.35 M(-4.7%) |
| Sept 2021 | - | $3.87 M(-11.8%) | $16.10 M(+2.8%) |
| June 2021 | - | $4.39 M(+33.9%) | $15.66 M(-0.7%) |
| Mar 2021 | - | $3.28 M(-28.4%) | $15.77 M(-3.9%) |
| Dec 2020 | $16.41 M(+17.7%) | $4.57 M(+33.5%) | $16.41 M(+3.9%) |
| Sept 2020 | - | $3.43 M(-23.7%) | $15.79 M(-0.7%) |
| June 2020 | - | $4.49 M(+14.7%) | $15.90 M(+8.2%) |
| Mar 2020 | - | $3.92 M(-1.1%) | $14.69 M(+5.4%) |
| Dec 2019 | $13.94 M(+5.3%) | $3.96 M(+12.1%) | $13.94 M(+5.3%) |
| Sept 2019 | - | $3.53 M(+7.4%) | $13.23 M(+3.2%) |
| June 2019 | - | $3.29 M(+4.0%) | $12.83 M(-1.1%) |
| Mar 2019 | - | $3.16 M(-3.0%) | $12.98 M(-2.0%) |
| Dec 2018 | $13.24 M | $3.26 M(+4.2%) | $13.24 M(+7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $3.13 M(-9.0%) | $12.36 M(+2.7%) |
| June 2018 | - | $3.44 M(+0.5%) | $12.03 M(+7.2%) |
| Mar 2018 | - | $3.42 M(+43.9%) | $11.23 M(+12.1%) |
| Dec 2017 | $10.02 M(+55.8%) | $2.38 M(-15.0%) | $10.02 M(+6.3%) |
| Sept 2017 | - | $2.80 M(+6.2%) | $9.42 M(+16.0%) |
| June 2017 | - | $2.63 M(+19.0%) | $8.12 M(+16.6%) |
| Mar 2017 | - | $2.21 M(+24.2%) | $6.96 M(+8.3%) |
| Dec 2016 | $6.43 M(+19.9%) | $1.78 M(+19.2%) | $6.43 M(-5.5%) |
| Sept 2016 | - | $1.49 M(+1.2%) | $6.81 M(-5.9%) |
| June 2016 | - | $1.48 M(-12.1%) | $7.24 M(+13.2%) |
| Mar 2016 | - | $1.68 M(-22.1%) | $6.39 M(+19.1%) |
| Dec 2015 | $5.36 M(+31.6%) | $2.16 M(+12.1%) | $5.36 M(+38.6%) |
| Sept 2015 | - | $1.92 M(+204.5%) | $3.87 M(-4.6%) |
| June 2015 | - | $631.50 K(-3.4%) | $4.06 M(-12.4%) |
| Mar 2015 | - | $653.80 K(-1.4%) | $4.63 M(+13.6%) |
| Dec 2014 | $4.08 M(+817.5%) | $662.80 K(-68.6%) | $4.08 M(+19.4%) |
| Sept 2014 | - | $2.11 M(+74.7%) | $3.41 M(+161.4%) |
| June 2014 | - | $1.21 M(+1109.8%) | $1.31 M(+1209.8%) |
| Mar 2014 | - | $99.70 K | $99.70 K |
| Dec 2013 | $444.30 K | - | - |
FAQ
- What is Zynerba Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Zynerba Pharmaceuticals?
- What is Zynerba Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Zynerba Pharmaceuticals?
What is Zynerba Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of ZYNE is $14.15 M
What is the all time high annual SG&A for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high annual selling, general & administrative expenses is $16.41 M
What is Zynerba Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of ZYNE is $3.97 M
What is the all time high quarterly SG&A for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $4.57 M
What is Zynerba Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of ZYNE is -$1.12 B
What is the all time high TTM SG&A for Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals all-time high TTM selling, general & administrative expenses is $16.41 M